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Summary
Obesity is a global epidemic associated with over 200 health complications and a
significant risk of developing cardiovascular disease (CVD), partly by increasing
classical risk factors such as lipid and glucose levels and blood pressure. Weight
loss through lifestyle interventions, pharmacotherapy and/or bariatric surgery
improves CV risk factors. Cardiovascular outcome trials (CVOTs) of anti-obesity
medications aim to evaluate the CV safety and benefits of pharmacotherapy. Many
CVOTs in obesity have either failed to demonstrate a CV benefit or have been
terminated prematurely because of safety issues, prompting regulatory agencies to
define new requirements (based on those for CVOTs in type 2 diabetes [T2D]).
CVOTs of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in T2D have
demonstrated that some GLP-1RAs reduce CV risk and may help inform future
CVOTs in obesity, given the approval of liraglutide 3.0 mg for obesity. In this
review, the evidence for the link between obesity and CVD is considered in the
context of studies showing that weight loss improves markers of CV risk and risk
of adverse CV events. The review also examines the CVOTs in obesity that have
been conducted to date and those under way, such as the SELECT trial with
subcutaneous semaglutide of 2.4 mg.
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1 | INTRODUCTION
Globally, approximately 650 million people are living with obesity1;
the global economic cost of obesity is 1.8 trillion Euros, equivalent
to 2.8% of gross domestic product.2 Excess adipose tissue may lead to
increased adipokine synthesis, lipid production, activation of the sym-
pathetic nervous and renin–angiotensin–aldosterone systems and to a
low-grade systemic inflammatory state.3 Hence, obesity is associated
with over 200 complications,4 a number of which are risk factors for
cardiovascular disease (CVD).
This article reviews the association between obesity and risk for
CVD, explores the effect of weight loss on CVD risk and overviews
cardiovascular outcome trials (CVOTs), to date, in people with obesity.
2 | ANTHROPOMETRIC INDICATORS OF
OBESITY AND CV RISK
Obesity is an established risk factor for atherosclerosis, ischaemic
heart disease, congestive heart failure and stroke.4 In a pooled analy-
sis of three prospective cohort studies (Nurses' Health Study I and II
and the Health Professionals Follow-up Study) that included 225 072
people, those who were classified as having overweight (body mass
index [BMI] 25.0–29.9 kg m−2), obesity Class I (BMI 30.0–34.9 kg m−2)
or obesity Class II (BMI > 35.0 kg m−2) had increased risk of CV death
than had people with healthy weight (BMI 18.5–24.9 kg m−2), with
hazard ratio (HR) [95% confidence interval, CI]: 1.2 [1.15, 1.28], 1.6
[1.52, 1.74] and 2.7 [2.53, 2.97], respectively.5 The Cardiovascular
Disease Lifetime Risk Pooling Project reported that middle-aged men
with obesity (BMI 30.0–39.9 kg m−2) or severe obesity
(BMI > 40.0 kg m−2) had shorter overall survival time (27.2 and
23.4 years) than had those with healthy weight (BMI 18.5–24.9 kg m−2;
29.1 years); those with severe obesity had greater risk for CV mortal-
ity than those with obesity or overweight (HR [95% CI]: 2.32 [1.69,
3.18] vs. 1.41 [1.28, 1.55] or 1.10 [1.02, 1.19]).6
The pan-European EPIC-CVD (European Prospective Investiga-
tion into Cancer and Nutrition—Cardiovascular Disease) study demon-
strated that people with overweight (BMI ≥ 25 to <30 kg m−2) or
obesity (BMI ≥ 30 kg m−2) had a higher risk of coronary heart disease
(CHD) than those with healthy weight (BMI ≥ 18.5 to <25 kg m−2)
(HR [95% CI]: 1.26 [1.17, 1.36] and 1.28 [1.05, 1.56], respectively),
even in the absence of metabolic syndrome, suggesting that obesity is
an independent risk factor for CHD.7 A meta-analysis of Mendelian
randomization studies suggested that each standard deviation unit
increase in BMI is associated with a 20% increased risk of coronary
artery disease (CAD), independently of other risk factors.8
The INTERHEART study reported that abdominal obesity
(waist/hip ratio > 0.90 in men and >0.83 in women) is also an impor-
tant predictor of adverse CV outcomes and is only modestly corre-
lated to BMI.9 Abdominal obesity was significantly related to acute
myocardial infarction (MI; HR [99% CI]: 1.62 [1.45, 1.80] for the top
vs. lowest tertile and 1.12 [1.01, 1.25] for the middle vs. lowest tertile;
population attributable risk 20.1% for the top two tertiles vs. lowest
tertile).9 Waist circumference was shown to correlate with direct mea-
surement of visceral adiposity10 and is also an independent risk factor
for CHD.7
It should be noted that the above-mentioned studies included US
and European populations and risks may be different for other
populations, including Asian populations who have been observed to
have greater health risks at lower BMI than have Western
populations.11
3 | THE PATHOPHYSIOLOGY OF OBESITY
AND CVD
Both abdominal (visceral) fat and insulin resistance may contribute to
CVD in obesity. Visceral fat is predominantly white adipose tissue
(WAT). WAT has a prominent role in energy homeostasis; it is a reser-
voir for energy storage, senses energy demands and secretes endo-
crine factors such as leptin to regulate appetite.12 In obesity,
prolonged positive energy balance increases both the size and number
of adipocytes. In addition, obesity can cause WAT to become severely
dysfunctional; unhealthy expansion of WAT is associated with local
hypoxia, altered adipokine secretion and mitochondrial dysfunction,
which can lead to inflammation and fibrosis within adipose tissue.13
Eventually, adipose tissue expansion becomes impossible owing to cell
and tissue expansion limitations, and this induces ectopic fat deposi-
tion in the muscle, liver and pancreas. This is known as lipotoxicity
and is associated with insulin resistance in the muscle and liver,
together with beta-cell dysfunction, increasing the risk for type 2 dia-
betes (T2D). The resultant systemic chronic inflammatory state then
results in endothelial dysfunction mediated through adipokines. Fat
accumulation, insulin resistance, inflammation and dyslipidaemia may,
therefore, all contribute to the development of atherosclerosis and
CVD.14
As adipose tissue accumulates, numerous alterations in cardiac
structure occur in individuals with obesity, even in the absence of co-
morbidities.15 In obesity, circulating blood and plasma volume and car-
diac output increase to meet increased metabolic needs. This then
increases venous return to the ventricles, producing dilation of these
cavities and increasing wall tension.15 This, together with increased
blood pressure (BP), results in left ventricular (LV) hypertrophy, which
may be followed by systolic dysfunction. Diastolic dysfunction is also
common in obesity and may lead to heart failure with preserved ejec-
tion fraction.15 These functional, morphological and metabolic abnor-
malities related to the heart that are caused by obesity can result in
obesity cardiomyopathy (OCM). OCM is caused by changes to the
structure and function of the heart in the absence of other cardiac risk
factors, such as coronary artery disease, hypertension and significant
valvular disease. The American Heart Association classifies OCM as a
subtype of dilated cardiomyopathy, characterized by alterations in
ventricular morphology and function including LV dilatation, eccentric
or concentric LV hypertrophy, LV systolic and diastolic dysfunction
and right ventricular dysfunction, occurring in the setting of morbid
obesity (BMI ≥ 35 kg m−2).16 OCM is associated with increased risk
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for heart failure.16 Obese heart failure with preserved ejection frac-
tion is a distinct subtype of heart failure related to OCM.17 A study of
cardiac structure and LV function in 74 normotensive people with
BMI ≥ 35 kg m−2 (i.e. people with OCM) with or without heart failure
identified five factors that increase the risk of developing heart failure:
the duration of morbid obesity, LV internal dimension in diastole, LV
end-systolic wall stress, left atrial dimension and right ventricular
internal dimension.16 Therefore, systemic and pulmonary hyperten-
sion, CHD and heart failure all occur with disproportionately high fre-
quency in obesity, increasing the risk of sudden cardiac death.15
4 | EFFECTS OF WEIGHT LOSS ON CVD
RISK FACTORS AND OUTCOMES
Excess adiposity leads to major classical risk factors and common
chronic diseases such as hypertension, dyslipidaemia, T2D, CHD and
chronic kidney disease (Figure 1).3 Excess adiposity is also an impor-
tant source of cytokines and contributes to the proinflammatory
milieu present in people with obesity.18 Hence, it is hypothesized that
weight reduction and the subsequent reduction in proinflammatory
markers and inflammation may lead to improvements in CVD risk fac-
tors (soft endpoints), which in turn may lead to better CV outcomes
(hard endpoints).
4.1 | Intentional weight loss
Observational studies have suggested that weight loss is associated
with improvements in CVD risk factors and adverse CV events.19,20 A
prospective observational study that followed up people with over-
weight (BMI ≥ 27 kg m−2) and T2D for 12 years reported a 25%
reduction in total mortality with intentional weight loss.19 In contrast,
a meta-analysis of 26 studies demonstrated that intentional weight
loss in people with overweight (BMI ≥ 25 to <30 kg m−2) had a neutral
effect on all-cause mortality (relative risk 1.01).20
4.2 | Lifestyle interventions
The Look Action for Health in Diabetes (Look AHEAD) trial, which
studied the effects of intensive lifestyle intervention (ILI) over 10 years
in people with overweight (BMI > 25 kg m−2) or obesity
(BMI > 27 kg m−2) and T2D, observed no significant reductions in the
incidence of CVD in the total population (p for trend = 0.17); however,
a post hoc analysis suggested an association between the magnitude
of weight loss and incidence of CVD21 (Table 1). Furthermore, ILI
resulted in reduced medication usage for diabetes, hypertension and
dyslipidaemia at 1 year.22 The Chinese Da Qing study assessing the
long-term effects of a 6-year trial of lifestyle intervention (diet ± exer-
cises) in people with impaired glucose tolerance and mean BMI of
25.7 kg m−2 (weight loss encouraged only in those with
BMI > 25 kg m−2) showed that after 30 years of follow-up, people
who received the lifestyle intervention had delay in diabetes onset,
reduced incidence of CVD events and deaths and increased life
expectancy versus people in the control group23 (Table 1).
4.3 | Bariatric surgery
Bariatric surgery is an effective strategy for weight reduction for peo-
ple with severe obesity (BMI ≥ 35.0 kg m−2), and long-term studies
demonstrate that it is associated with improvements in several CVD
risk factors.26 A retrospective observational study of 1330 people
with no history of CVD undergoing bariatric surgery between 2010
and 2016 suggested that those with severe obesity and high risk of
CVD benefit more from the procedure than those with obesity and
low CV risk.27
F IGURE 1 Association of excess adiposity with major risk factors and chronic conditions.3 Common chronic diseases are shown in red boxes.
The dashed arrow denotes an indirect association
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Two- and 10-year follow-up data from the Swedish Obese Sub-
jects (SOS) study demonstrated that bariatric surgery leads to T2D
remission, as well as improvements in hypertension and hyper-
triglyceridaemia in some cases (at 10 years, 36%, 19% and 46% of
people who had surgery achieved remission from these conditions
vs. 13%, 11% and 24% who did not have surgery, respectively).28 A
5-year follow-up of the randomized controlled STAMPEDE study
involving 150 people with T2D and BMI of 27–43 kg m−2 demon-
strated that HbA1c ≤ 6.0% was achieved by 2/38 (5%) people who
received medical therapy alone versus 14/49 (29%) who underwent
gastric bypass and 11/47 (23%) of those who had sleeve gastrec-
tomy.29 In the SOS study, after a median follow-up of 14.7 years, bar-
iatric surgery was associated with lower incidence of CV death
(p = 0.002) and MI or stroke (p < 0.001) versus no surgery (Table 1).25
A meta-analysis of randomized controlled trials with a 2-year follow-
up demonstrated that bariatric surgery, versus no surgery, led to a
higher rate of T2D remission.30 A retrospective cohort study, which
included a mean follow-up of 7.1 years, demonstrated that bariatric
surgery, compared with no surgery, was associated with mortality risk
reductions of 56% and 92%, in people with CAD and T2D,
respectively.31
Of note, a major limitation of the trials on bariatric surgery is that
a majority of them are not randomized controlled studies.
4.4 | Effects of anti-obesity medications on CVD risk
factors
Given as an adjunct to lifestyle intervention, use of anti-obesity medi-
cations (AOMs) improves CVD risk factors. The four large-scale, Phase
3 RIO (Rimonabant In Obesity) trials32 showed that rimonabant
(20 mg; now withdrawn) improved glycaemic control, lipid profile and
high-sensitivity C-reactive protein (hsCRP) levels and also reduced the
prevalence of metabolic syndrome. Covariate analyses of the RIO-
Lipids trial suggested that only 60% of the increase in high-density
lipoprotein cholesterol (HDL-C) and 45% of the reduction in triglycer-
ides could be explained by the observed weight loss.33 Sibutramine
(20 mg; now withdrawn) also improved HbA1c, HDL-C and triglycer-
ides in a placebo-controlled double-blind trial.34 In the XENDOS trial,
orlistat 120 mg, compared with placebo, improved waist circumfer-
ence, systolic and diastolic BP (SBP/DBP), fasting plasma glucose
(FPG) and lipids and improved glucose tolerance, over 4 years.35
The COR-I trial of naltrexone–bupropion 32 mg/360 mg
observed improvements in FPG, fasting insulin and insulin resistance
versus placebo after 56 weeks.36 The SCALE Obesity and Prediabetes
study of liraglutide of 3.0 mg, compared with placebo, demonstrated
improvements in HbA1c, FPG, SBP/DBP, fasting lipids, hsCRP, plas-
minogen activator inhibitor-1 and adiponectin after 56 weeks.37 At
160 weeks, more people in the liraglutide of 3.0 mg group versus pla-
cebo had regressed from prediabetes to normoglycaemia (66%
vs. 36%, respectively).38
In 1997, fenfluramine–phentermine (fen-phen) was withdrawn
from the market by its manufacturer because of reports linking its use
with valvular regurgitation.39 A Mayo Clinic case series showed signif-
icant valvular heart disease in 24 women who had taken fen-phen for
≥6 months.40 A subsequent report revealed that 113/132 (86%) peo-
ple who had taken fen-phen for 6 to 24 months had aortic and/or
mitral regurgitation.41 Dexfenfluramine, the active isomer of fenflur-
amine, was also withdrawn from the global market following reports
of pulmonary arterial hypertension in addition to valvular regurgita-
tion.41 These reports have a clear geographic distribution in that they
were all reported in the United States. This may be because in Europe,
dexfenfluramine and fenfluramine were only approved for use for
≤12 weeks, and hence, cardiac valvulopathy was not a safety issue.42
TABLE 1 Obesity trials with positive outcomes
Obesity trials Results
Look AHEAD post hoc
analysis21
People who achieved ≥10% weight loss compared with those who did not achieve ≥10% weight loss had:
• a significant 21% reduction (95% CI [0.64, 0.98]) in the risk of CVD
• a significant 24% risk reduction (95% CI [0.63, 0.91]) for the first occurrence of nonfatal acute MI or stroke,
hospitalization for angina or CHF, or CV death plus coronary artery bypass grafting, carotid endarterectomy,
percutaneous coronary intervention, peripheral vascular disease or total mortality
Chinese Da Qing study23 Lifestyle intervention (diet and/or exercise) compared with control resulted in:
• median delay in diabetes onset: 3.96 years (95% CI [1.25, 6.67])
• fewer CVD events (hazard ratio 0.74, 95% CI [0.59, 0.92])
• lower incidence of microvascular complications (0.65, 95% CI [0.45, 0.95], p = 0.025)
• fewer CVD deaths (0.67, 95% CI [0.48, 0.94], p = 0.022)
• fewer all-cause deaths (0.74, 95% CI [0.61, 0.89], p = 0.0015)
• average increase in life expectancy of 1.44 years (95% CI [0.20, 2.68], p = 0.023)
• BMI reduction of −1.1 kg m−2
SCOUT trial24 Cardiovascular mortality for responders (who lost weight):
• hazard ratio (per 1 kg weight loss): 0.93 95% CI [0.89, 0.97], p = 0.001
SOS trial25 Bariatric surgery vs. no surgery was associated with:
• reduced number of CV deaths (28 events in 2010 participants in surgery group vs. 49 events in 2037 participants in
control group; adjusted HR 0.47, 95% CI [0.29, 0.76], p = 0.002)
• lower number of CV events (199 in 2010 vs. 234 in 2037; adjusted HR 0.67, 95% CI [0.54, 0.83], p < 0.001)
Abbreviations: CHF, congestive heart failure; CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; MI, myocardial infarction.
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The use of dexfenfluramine or fenfluramine together with another
AOM such as phentermine (‘phen’) was contraindicated in Europe,
and off-label use in this way was rare; hence, the fen-phen issue was
also not reported.42
The regulatory standards required for licensing of an anti-obesity
drug are much stricter than for other drugs. The safety criteria are par-
ticularly stringent because of the poor track record of AOMs
approved so far. Anti-obesity drugs are constantly monitored for any
potential safety issues that would necessitate drug withdrawals.42,43
5 | CARDIOVASCULAR OUTCOME TRIALS
IN PEOPLE WITH OBESITY
In 2010, sibutramine was withdrawn from the market by its manu-
facturer following clinical trial data suggesting an increased risk for
stroke and MI with its use.44 The Sibutramine Cardiovascular
Outcomes Trial (SCOUT) in 9804 people with overweight (BMI
25.0–26.9 kg m−2) or obesity (BMI 27.0–45.0 kg m−2) demonstrated
an increased risk of nonfatal MI and nonfatal stroke in those with
pre-existing CVD receiving sibutramine of 10–15 mg daily.45 The
SCOUT trial had no stopping criteria, with nonresponders (i.e. those
who did not lose weight) continuing therapy.45 In a post hoc analy-
sis, which only analysed responders, weight loss with sibutramine
was associated with a reduction in CV mortality for a 4- to 5-year
period following trial completion (including people with established
CVD; Table 1).24
After rimonabant (20 mg) was granted marketing authorization in
the European Union (EU) in 2006, its effect on CV outcomes was
evaluated in the Comprehensive Rimonabant Evaluation Study of Car-
diovascular Endpoints and Outcomes (CRESCENDO) CVOT. The trial
was discontinued prematurely because of serious adverse event con-
cerns raised by regulatory authorities.46 The marketing of rimonabant
was suspended, and the drug subsequently withdrawn from use in the
EU in 2009.47 A meta-analysis of all published clinical trial data sug-
gests that although rimonabant of 20 mg day−1 was associated with a
4.7-kg greater weight reduction after 1 year versus placebo, it
increased the risk of depressed mood disorders and anxiety.48
The findings from these early trials and clinical experience with
AOMs contributed to increased demand for robust and long-term CV
and safety outcome investigations.
5.1 | Regulatory requirements for obesity CVOTs
from 2012 onwards
In 2012, the Food and Drug Administration (FDA) set out new
requirements for CVOTs in obesity,49 based on similar guidance for
CVOTs in T2D.50 A requirement for approval is that the upper bound
of the 95% CI for the estimated risk of major adverse cardiovascular
events (MACE) compared with placebo should be less than 1.3. Strat-
egies to ensuring that CVOTs include a sufficient number of events
for detection of differences in MACE are as follows: pooling safety
databases across Phase 2 and 3 clinical trials and performing a meta-
analysis of all CV events with prospective adjudication by an indepen-
dent, blinded committee and careful enrolment of people at high CVD
risk.49 In 2015, the European Medicines Agency (EMA) provided simi-
lar recommendations for evaluating CV safety of new medicinal prod-
ucts for the long-term treatment of certain CV and metabolic diseases
(Figure 2).51
5.2 | Challenges and requirements for the design of
obesity CVOTs
Some of the trial design challenges and requirements set out by the
Department of Health and Human Services (DHHS) are outlined
below.52
F IGURE 2 EMA recommendations
for CV safety evaluation of new
medicinal products.51 CV,
cardiovascular; HR, hazard ratio
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5.2.1 | Superiority versus noninferiority trial
The primary objective of the trial should be to show CV benefit
(superiority to placebo) or to rule out an unacceptable increase in
CV risk (noninferiority to placebo). A larger sample size will be
required to demonstrate superiority than to show noninferiority.
The DHHS document contains a table with estimated sample sizes
for both number of primary CV events and patient-years needed
to observe the events. To show noninferiority, one needs to con-
sider the degree of unacceptable CV risk that should be ruled out.
The table in the DHHS document also provides the excess CV risk,
as measured by the risk difference, that can be ruled out.
5.2.2 | Primary endpoint
Three-point MACE (CV death, nonfatal MI and nonfatal stroke) should
be the primary endpoint for the trials designed to show the CV bene-
fit of the drugs. Trials sometimes include other endpoints such as hos-
pitalization for unstable angina, heart failure and/or arterial or
coronary revascularizations. These are more subjective endpoints and
are challenging to define. The variability of these softer endpoints can
bias the trial results towards the null, which is particularly concerning
for noninferiority trials.
5.2.3 | Baseline characteristics of patient population
An event-driven CVOT would require large number of subjects and/or
long treatment duration to reach the required number of MACE
events. Hence, the trial needs to be enriched with subjects with high
risk for MACE to capture more events while subjects are taking the
drug. Although this may reduce or limit generalizability of the results,
it will allow acceptable CV safety to be demonstrated in a high-risk
population.
5.2.4 | Timing of interim analyses
The weight-loss efficacy of an obesity drug is usually the greatest at
6–9 months after initiation of the drug and often diminishes thereaf-
ter. This means that the CV efficacy/safety profile of the drug may
change over time during the course of the trial. Although an interim
analysis may be statistically valid, the timing of such analysis needs to
be determined carefully as the results may provide the basis for regu-
latory approval of the drug.
5.2.5 | Primary analysis population
While analysing the primary results of a CVOT, it is important to
identify the appropriate patient population, particularly because of
the high dropout rates seen in trials of obesity drugs. Although an
intention-to-treat population is considered the most appropriate
for primary efficacy analysis, an on-treatment population may pro-
vide more information regarding the true CV efficacy/safety of
the drug.
5.2.6 | Global representation within the trial
population
A trial should be designed in such a way that the data produced can
be applied to different populations around the world.
5.3 | CVOTs in obesity since 2012
Several CVOTs in people with overweight/obesity have been initiated
since the new requirements were introduced (Figure 3). The Light
study, which evaluated naltrexone–bupropion 32 mg/360 mg, was
unblinded early and prematurely terminated because data from an
interim 25% analysis showing a 41% reduction in MACE were acci-
dentally ‘leaked’.53 Results from the completed, preplanned 50%
interim analysis were less favourable than the earlier data cut-off and
did not establish noninferiority for MACE (HR [95% CI]: 0.88 [0.57,
1.34]).53 The AQCLAIM trial evaluating phentermine–topiramate
extended release was authorized by the EMA in 2013, but the trial
will probably not proceed.54 Discussions between the manufacturer
and the regulators are ongoing about a potential retrospective obser-
vational study rather than a CVOT.54
One of the major issues with obesity CVOTs and trials of obesity
drugs in general is the high treatment discontinuation rates. This may
be due to the fact that participants entering the trials are looking for a
‘quick fix’, and if they do not experience rapid weight loss they may
drop out of the trial. One study looking into ways of maximizing par-
ticipant retention in long-term, Phase 3 clinical trials of weight loss
agents concluded that use of a dietitian screening interview to iden-
tify participants at high risk of dropout and monthly support confer-
ence calls to discuss strategies to enhance adherence resulted in
better participant retention rates.57
The only completed CVOT to date is the CAMELLIA-TIMI-61
study, which confirmed CV safety but no CV benefit for lorcaserin.55
Of note, the FDA requested the withdrawal of lorcaserin from the
market in January 2020 owing to concerns over cancer risk from the
same trial.58
Another issue is that BMI is not a perfect reflection of adipos-
ity as it does not differentiate between adipose tissue and muscle
mass. Although BMI is widely accepted to define overweight and
obesity, it is not applicable globally with lower BMI associated with
health issues in South Asians compared with Western populations.
The use of an alternative measure of adiposity (e.g. waist/hip ratio
or body volume index) in obesity CVOTs may, therefore, make
their outcomes more widely applicable. Of note, in the obesity
CVOTs conducted to date, more than 85% of the trial populations
are White.53,55
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Once-weekly semaglutide 2.4 mg (approved for the treatment
of T2D at 0.5 and 1.0 mg)59 is currently under investigation for
the treatment of obesity in the Semaglutide Effects on Heart Dis-
ease and Stroke in Patients With Overweight or Obesity (SELECT)
CVOT.56 This trial aims to enrol 17 500 people with obesity and
pre-existing CVD and differs notably from previous CVOTs in obe-
sity (Figure 4).
6 | CARDIOVASCULAR OUTCOME TRIALS
IN TYPE 2 DIABETES
Several CVOTs of T2D drugs have demonstrated CV benefit and
safety.60 Post hoc analyses of DECLARE-TIMI 58 (dapagliflozin)61 that
stratified participants by baseline BMI of 18.5 to <25, 25 to <30,
30 to <35, 35 to <40 and ≥40 kg m−2 showed that increasing BMI
F IGURE 3 Overview of CVOTs in obesity since 2012. BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; HR, hazard
ratio; MACE, major adverse cardiovascular event
F IGURE 4 Key features of the SELECT trial and potential implications. CV, cardiovascular; CVOT, cardiovascular outcomes trial; GLP-1RA,
glucagon-like peptide-1 receptor agonist; HFpEF, heart failure with preserved ejection fraction; MACE, major adverse cardiovascular event; T2D,
type 2 diabetes
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category was associated with a high risk of CVD/hospitalization
for heart failure. A subanalysis of the CANVAS programme, which
tested the consistency of canagliflozin across baseline BMI categories
of <25, 25 to <30 and ≥30 kg m−2 showed that there was no
difference in treatment-related outcomes across the BMI levels.62
Post hoc analysis of LEADER/SUSTAIN 663 data stratifying
participants by baseline BMI (<25, ≥25 to <30, ≥30 to <35 and
≥35 kg m−2) showed that liraglutide and semaglutide improved CV
and renal outcomes with no apparent differences across BMI
groups. However, subgroup analysis of the EMPA-REG OUTCOME
(empagliflozin) trial demonstrated a borderline trend for better out-
comes for people with low BMI (<30 kg m−2; HR for primary outcome
0.74) compared with those with high BMI (≥30 kg m−2; HR for pri-
mary outcome 0.98).64
Data from seven CVOTs in T2D with glucagon-like peptide-1
receptor agonists (GLP-1RAs) (Figure 5) show that they have benefi-
cial effects on CVD risk, all-cause mortality and renal outcomes.65
Liraglutide (3.0 mg) was subsequently approved for obesity (by the
FDA in 201466 and EMA in 201567), and Phase 3 trials of semaglutide
of 2.4 mg for weight management in people with or without T2D are
underway.
7 | CONCLUSION
There is robust evidence to show that obesity and CVD are strongly
linked and that weight loss improves surrogate markers of CVD risk.
Post hoc analyses of large trials, such as Look AHEAD, SCOUT and
the SOS, suggest that weight loss is positively correlated with CV ben-
efits.21,24,25 Several approved AOMs are considered appropriate for
people with obesity and CVD; liraglutide of 1.8 mg reduced the risk of
CV events in people with T2D in the LEADER trial, and this was
accepted as evidence to support the CV safety of liraglutide of 3.0 mg
by the regulators. Although bariatric surgery and liraglutide of 3.0 mg
have been shown to improve CVD risk factors, more data on CV
safety are lacking.68,69 Adoption of AOMs by prescribers is still very
low as compared with adoption of glucose-lowering agents for T2D.70
Orlistat and liraglutide 3.0 mg are considered most appropriate for
people with CVD,68 but until further CVOTs in obesity are complete,
it is unlikely that treatment algorithms and prescribing habits will evo-
lve. Of note, no CVOT has yet demonstrated superiority of an AOM
versus placebo in obesity. Although the ongoing SELECT trial holds
promise, the focus on people with a high risk of CV events is an inher-
ent limitation, and it may reduce the trial's generalizability to real-
world practice.60
It is clear that large sample sizes and long trial durations are
required to observe an adequate number of adverse CV events to
enable suitably powered statistical comparison of the AOM being
evaluated and its comparator, even if the population is enriched with
patients at high risk of adverse CV events. If future obesity CVOTs
are able to demonstrate reduction in observed risk of adverse CV out-
comes and a CV benefit, we may see a gradual increase in the adop-
tion of AOMs and updated guideline recommendations (as has
occurred with the diabetes CVOTs).
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